53 related articles for article (PubMed ID: 19147757)
1. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
2. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma.
Spaan I; Timmerman LM; Kimman T; Slomp A; Cuenca M; van Nieuwenhuijzen N; Moesbergen LM; Minnema MC; Raymakers RA; Peperzak V
Blood Adv; 2021 Jun; 5(12):2593-2607. PubMed ID: 34152396
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.
Aveic S; Pantile M; Polo P; Sidarovich V; De Mariano M; Quattrone A; Longo L; Tonini GP
Cancer Cell Int; 2018; 18():63. PubMed ID: 29713246
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of multiple myeloma.
Dolloff NG; Talamo G
Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.
Flietner E; Wen Z; Rajagopalan A; Jung O; Watkins L; Wiesner J; You X; Zhou Y; Sun Y; Kingstad-Bakke B; Callander NS; Rapraeger A; Suresh M; Asimakopoulos F; Zhang J
Sci Rep; 2022 Jun; 12(1):10616. PubMed ID: 35739276
[TBL] [Abstract][Full Text] [Related]
6. Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.
Borisov N; Sergeeva A; Suntsova M; Raevskiy M; Gaifullin N; Mendeleeva L; Gudkov A; Nareiko M; Garazha A; Tkachev V; Li X; Sorokin M; Surin V; Buzdin A
Front Oncol; 2021; 11():652063. PubMed ID: 33937058
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
[TBL] [Abstract][Full Text] [Related]
8. Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?
Vyas D; Deshpande K; Chaturvedi L; Gieric L; Ching K
J Clin Med Res; 2016 Feb; 8(2):162-7. PubMed ID: 26767086
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of genome-wide DNA methylation analysis in epigenetically modulated phenotypes in lung cancer.
Dai SP; Xie C; Ding N; Zhang YJ; Han L; Han YW
Med Oncol; 2015 Jun; 32(6):615. PubMed ID: 25926333
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis.
Vyas D; Laput G; Vyas AK
Onco Targets Ther; 2014; 7():1015-23. PubMed ID: 24959088
[TBL] [Abstract][Full Text] [Related]
11. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies.
Kalff A; Spencer A
Blood Cancer J; 2012 Sep; 2(9):e89. PubMed ID: 22961061
[TBL] [Abstract][Full Text] [Related]
12. The mesenchymal tumor microenvironment: a drug-resistant niche.
Cukierman E; Bassi DE
Cell Adh Migr; 2012; 6(3):285-96. PubMed ID: 22568991
[TBL] [Abstract][Full Text] [Related]
13. Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.
Zhang W; Huang P
Cancer Biol Ther; 2011 Jan; 11(2):150-6. PubMed ID: 21191189
[TBL] [Abstract][Full Text] [Related]
14. Environment-mediated drug resistance: a major contributor to minimal residual disease.
Meads MB; Gatenby RA; Dalton WS
Nat Rev Cancer; 2009 Sep; 9(9):665-74. PubMed ID: 19693095
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
